

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JACKSON *et al.*

Appl. No.: 10/701,844

Filed: November 4, 2003

For: **Chlamydia Protein, Gene  
Sequence and Uses Thereof**

Confirmation No.: 3069

Art Unit: 1645

Examiner: BASKAR, Padmavathi

Atty. Docket: 2479.0040002/EJH/C-K

**Second Supplemental Information Disclosure Statement  
Under 37 C.F.R. § 1.97(c)**

*Mail Stop Amendment*

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on November 22, 2006 in connection with the above-captioned application.

Copies of documents **FP4** to **FP7** and **NPL36** to **NPL57** are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, **US8** to **US10**, cited on the attached IDS Form, PTO/SB/08A, are not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the

effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants would like to bring to the attention of the Examiner that, for the following document, the publication month could not be determined to the best of the Applicants' ability:

SMITH, J.A., "Analysis of Proteins," in Short Protocols in Molecular Biology 3rd ed., Ausubel, F.M., et al., eds. John Wiley & Sons, Inc. United States (1997).

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first Office Action on the


merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Elizabeth J. Haanes, Ph.D.

Attorney for Applicants

Registration No. 42,613

Date: August 1, 2007

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600

704621\_1